SAN DIEGO, Sept. 17 Ardea Biosciences, Inc.(Nasdaq: RDEA) announced today that Barry D. Quart, PharmD, President and CEOof Ardea Biosciences, will present at two upcoming investor conferences.
About Ardea Biosciences, Inc.
Ardea Biosciences, Inc., of San Diego, California, is a biotechnologycompany focused on the discovery and development of small-moleculetherapeutics for the treatment of HIV, gout, cancer and inflammatory diseases.We have five product candidates in clinical trials and others in preclinicaldevelopment and discovery. Our most advanced product candidate is RDEA806, anon-nucleoside reverse transcriptase inhibitor (NNRTI), which has successfullycompleted a Phase 2a study for the treatment of patients with HIV. We haveevaluated our second-generation NNRTI for the treatment of HIV, RDEA427, in ahuman micro-dose pharmacokinetic study and have selected it for clinicaldevelopment. RDEA594, our lead product candidate for the treatment of gout, isbeing evaluated in a Phase 1 clinical trial and is believed to be an inhibitorof the URAT1 transporter in the kidney, which is responsible for regulation ofuric acid levels. We are evaluating our lead MEK inhibitor, RDEA119, in aPhase 1 study in advanced cancer patients, and have completed a Phase 1 studyin normal healthy volunteers as a precursor to trials in patients withinflammatory diseases. Lastly, we have evaluated our second-generation MEKinhibitor for the treatment of cancer and inflammatory diseases, RDEA436, in ahuman micro-dose pharmacokinetic study and have selected it for clinicaldevelopment.
Statements contained in this press release regarding matters that are nothistorical facts are "forward-looking statements" within the meaning of thePrivate Securities Litigation Reform Act of 1995. Because such statements aresubject to risks and uncertainties, actual results may differ materially fromthose expressed or implied by such forward-looking statements. Such statementsinclude, but are not limited to, statements regarding our goals, including theexpected properties and benefits of RDEA806, RDEA427, RDEA594, RDEA119,RDEA436 and our other compounds and the results of preclinical, clinical andother studies. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcome of preclinical andclinical studies, risks related to regulatory approvals, delays incommencement of preclinical and clinical studies, and costs associated withour drug discovery and development programs and business developmentactivities. These and other risks and uncertainties are described more fullyin our most recently filed SEC documents, including our Annual Report on Form10-K and our Quarterly Reports on Form 10-Q, under the headings "RiskFactors." All forward-looking statements contained in this press release speakonly as of the date on which they were made. We undertake no obligation toupdate such statements to reflect events that occur or circumstances thatexist after the date on which they were made.UBS Global Life Sciences Conference Date: Wednesday, September 24, 2008 Time: 1:00 p.m. Eastern Time Location: Grand Hyatt, New York Webcast: http://www.ibb.ubs.com Third Annual JMP Securities Healthcare Focus Conference Date: Tuesday, October 7, 2008 Time: 2:00 p.m. Eastern Time Location: Le Parker Meridian, New York Webcast: http://www.ljfevents.com/jmp/CompanyReg.htm
SOURCE Ardea Biosciences, Inc.